TSFAE24a:	Overall Summary of [Treatment-emergent Adverse Events] by Severity; Safety Analysis Set (Study jjcs - core)				
 	Active Study Agent 	Active Study Agent 	 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	
n (%) 	N=53 	N=73 	N=59 	
Subjects with ≥ 1 AE 	51 (96.2%) 	62 (84.9%) 	42 (71.2%) 	
 	 	 	 	
Severity 	 	 	 	
Severe 	3 (5.7%) 	12 (16.4%) 	3 (5.1%) 	
Moderate 	31 (58.5%) 	35 (47.9%) 	16 (27.1%) 	
Mild 	17 (32.1%) 	15 (20.5%) 	23 (39.0%) 	

Note: The worst severity event experienced by the subject is used. If a subject has all adverse events with missing severities, the subject is only counted as missing. 	
Note: The worst severity event experienced by the subject is used. If a subject has all adverse events with missing severities, the subject is only counted as missing.	
Note: The worst severity event experienced by the subject is used. If a subject has all adverse events with missing severities, the subject is only counted as missing.	
Note: The worst severity event experienced by the subject is used. If a subject has all adverse events with missing severities, the subject is only counted as missing.